Ebola disease
Orthoebolaviruses – Ebola virus, Sudan Virus, Bundibugyo virus and Taï Forest virus
Overview
Ebola disease is a disease caused by a group of orthoebolaviruses which causes severe, often fatal illness in humans.
Disease epidemiology
Ebola disease, first identified in 1976 in southern Sudan and the Democratic Republic of the Congo (DRC), primarily affects remote villages in Central and West Africa. Case fatality rate is around 50%, and ranges from 25% and 90%. On 15 May 2026, the World Health Organization (WHO) confirmed a new outbreak of Ebola disease caused by Bundibugyo virus in DRC. Uganda's Ministry of Health also confirmed lab-confirmed cases, including at least one death, in Kampala involving travellers from DRC. On 17 May 2026, the WHO declared the Ebola disease outbreak in the DRC and Uganda a public health emergency of international concern.
Pathogen(s)
Orthoebolaviruses are a single-stranded RNA virus belonging to the Filoviridae family. The genus Orthoebolavirus is divided into six species.
Four have caused human infections:
Zaire/Ebola virus (EBOV)
Sudan virus (SUDV)
Bundibugyo virus (BDBV)
Taï Forest virus (TAFV)
Two others have not caused human infections to date:
Reston virus (non-pathogenic in human) (RESTV)
Bombali virus (non-pathogenic in human) (BOMV)
The presumptive hosts of Ebolavirus are fruit bats of the family Pteropodidae.
Transmission
Transmission can occur through direct contact with:
Contact with infectious body fluids (blood, urine, vomitus, faeces, secretions, semen, breast milk) and/or organs of infected persons.
Contact with infected animals or their tissues.
Contact with contaminated surfaces or materials (e.g., needles and contaminated medical equipment).
Healthcare-associated transmission may occur during patient care, specimen collection, handling or laboratory processing, particularly through needlestick injuries, exposure to infectious blood or body fluids, improper cleaning or disinfection of medical equipment, reuse of needles, or contact with contaminated medical supplies. Appropriate infection prevention and control measures and laboratory biosafety precautions are essential to minimise these risks.
Incubation period: Typically 5 to 15 days; range is 2 to 21 days.
Infectious period: Infected individuals are not contagious during the incubation period and become infectious once they begin to develop symptoms. They remain infectious as long as the virus is present in the blood or body fluid. The virus can persist in semen of survivors and be transmitted sexually after recovery. Pregnant women who recover from Ebola disease may still carry the virus in breastmilk, or in pregnancy-related fluids and tissues.
Clinical features
Initial symptoms include sudden onset of fever, weakness, malaise, muscle pain, joint pain, headache and sore throat.
This can be followed by vomiting, diarrhoea, abdominal pain, rash, red eyes, confusion, shortness of breath, chest pain, impaired liver and renal function, internal and external bleeding.
Risk factors
Risk factors include:
Relevant travel to affected countries or regions with ongoing Ebola disease outbreaks.
Unprotected exposure to confirmed or suspect cases or their blood and body fluids.
Contact with infected animals or animal products, including preparation or consumption of bushmeat.
Contact with contaminated surfaces or materials (e.g., needles and contaminated medical equipment).
Diagnosis
Diagnosis during acute infection is primarily by detection of Orthoebolavirus by Reverse-transcription Polymerase Chain Reaction (RT-PCR) in blood specimens. Laboratory investigations at the primary care level should not be performed.
Samples can be sent to NPHL for diagnosis. NPHL will provide laboratory support and guidelines for testing, including protocols for specimen transport, testing and reporting.
Treatment and management
For all types of Ebola disease, supportive care remains as the mainstay treatment. This includes diagnosis and treatment of concomitant infections such as malaria or bacterial infections in febrile returning travellers, management of fluids and electrolytes, blood product support for haemorrhage, and support for multi-organ dysfunction, including renal replacement therapy if needed.
During outbreak settings, there are monoclonal antibodies (mAb114 (ansuvimabTM) or REGN-EB3 (InmazebTM) recommended by WHO to be used as adjunctive treatment in addition to supportive care where there is expected efficacy.
Precaution, prevention, and control
General advice
All staff who come into direct contact with a suspected or confirmed Ebola disease case or their body fluids, including (but not limited to) healthcare workers, persons responsible for transporting patients (e.g., ambulance staff), and cleaners should apply extra infection control measures and wear enhanced personal protective equipment (PPE) comprising of:
Disposable fluid-resistant hood to cover the head and neck areas (staff with long hair may wish to use head cover prior to wearing hood)
Eye protection gear (e.g., disposable downward face shields secured at forehead or goggles)
Fluid-repellent N95 mask
Inner and outer disposable fluid-resistant (AAMI 4) gown (should extend to below knee)
12-inch double nitrile or latex gloves certified for healthcare use (extended cuffs should reach up to mid forearm)
Disposable fluid resistant boot covers (should extend up to knee-height)
Patients who are under investigation for Ebola disease, pending transfer to the High-Level Isolation Unit (HLIU) at the National Centre for Infectious Diseases (NCID), should be isolated in an Airborne Infection Isolation Room (AIIR), at a minimum.
Only essential staff who have been pre-identified and trained in the donning and removal of PPE should attend to the patient. Staff attending to suspect Ebola disease cases should be closely monitored (e.g., twice daily temperature monitoring), even if they wear the appropriate PPE. Entry of non-essential staff to the patient’s room should be restricted. A register of all staff who enter the patient’s room should be maintained. Visitors should not be allowed.
Waste generated from suspect patients should be double bagged, sealed and disposed by a licensed waste-contractor. Environmental surfaces should be cleaned and disinfected using 5,000 ppm sodium hypochlorite. Disinfectants should be applied (not sprayed) before cleaning. Surface contaminated with blood, other body fluids, secretions or excretions spill, should be disinfected using 10,000 ppm sodium hypochlorite after the spill is removed using solidifiers or absorbent powder.
Personnel with skin or mucosal exposure to body fluids from a suspect Ebola disease case should immediately wash the affected skin surfaces with soap and water. Mucous membranes (e.g., conjunctiva) should be irrigated with copious amounts of water or eyewash solution. Exposed persons should immediately seek advice from an Infectious Diseases physician and report the exposure to CDA.
CDA will conduct contact tracing for contacts and take appropriate follow-up actions, such as quarantine, phone surveillance, or self-monitoring. Contacts may also be referred to NCID for assessment.
Vaccination
There are currently two licensed Ebola vaccines overseas, but these vaccines are not registered in Singapore.
Notification
Ebola disease is an emerging infectious disease and is legally notifiable in Singapore. All suspected cases of Ebola disease should be reported to CDA immediately and instructions will be provided on further management of these cases. Suspected cases will be transferred to NCID on a case-by-case basis. All confirmed Ebola disease cases will be managed at the High-Level Isolation Unit (HLIU) in NCID.
Who should notify:
Medical practitioners
Laboratories
When to notify:
On clinical suspicion
On laboratory confirmation
How to notify:
Please refer to the Infectious Disease Notification (opens in new tab) for more information.
Notification timeline:
Immediately
Resources
Get situation updates on Ebola disease from the WHO (opens in new tab).
